NCT00179608 is a Phase 1 clinical trial of CC-5013 in Malignant Melanoma, sponsored by Celgene.

Who is sponsoring NCT00179608?

NCT00179608 is sponsored by Celgene.

What drugs are being tested in NCT00179608?

Interventions in NCT00179608: CC-5013.

What condition does NCT00179608 study?

NCT00179608 studies Malignant Melanoma.

Is NCT00179608 still recruiting?

NCT00179608 is currently completed. Last updated 8 November 2019.

Last reviewed 2019-11-08 · How we verify

NCT00179608

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Completed Phase 1 Last updated 8 November 2019

What this trial tests

Phase 1 trial testing CC-5013 in Malignant Melanoma in 28 participants. Completed in 1 June 2007.

Timeline

1 September 2005

Primary endpoint
1 June 2007

1 June 2007

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	1 September 2005
Primary completion	1 June 2007
Estimated completion	1 June 2007
Sites	1 location across United States

Drugs / interventions tested

CC-5013 — full drug profile →

Conditions studied

Malignant Melanoma — all drugs for Malignant Melanoma →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Malignant Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will determine the MDT of intravenous DTIC when administered in combination with a fixed dose of oral lenalidomide in subjects with metastatic malignant melanoma previously untreated with systemic chemotherapy. This study will evaluate the safety and preliminary efficacy of the combination of lenalidomide and DTIC. Subjects will be receive lenalidomide for 14 consecutive days and DTIC on day one of each 21 day cycle.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mechanisms and Therapeutic Strategies to Overcome Immune Checkpoint Inhibitor Resistance in Melanoma, Head and Neck, and Triple-Negative Breast Cancers.
Voloshyna I, Tyagi A, Idga S, Wang N, et al · · 2025 · cited 1× · PMID 41799379 · DOI 10.33696/immunology.7.235

Verify or expand the search:

Other trials of CC-5013

Trials testing the same drug.

NCT00065351 — Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma · Phase 2 · completed
NCT00622336 — A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma · Phase 3 · completed
NCT00056160 — CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma · Phase 3 · completed
NCT00057616 — Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma. · Phase 3 · completed
NCT00044382 — Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome · Phase 2 · completed

Other recruiting trials for Malignant Melanoma

Currently open trials in the same condition.

NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06961006 — A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0 · Phase 2 · recruiting
NCT06974734 — A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies · Phase 1 · active not recruiting
NCT06980740 — Video-Tumorboard PLUS · recruiting
NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00179608 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 8 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00179608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing